The FDA said it's looking into the risk of severe hypocalcemia among patients on dialysis receiving denosumab (Prolia), citing the potential for severe outcomes, including hospitalization and death.

Calcium is a vital mineral that plays a crucial role in various bodily functions. It's essential for building strong bones, enabling muscle movement, nerve function, blood clotting, and heart health.

Please provide your email address to receive an email when new articles are posted on . The FDA issued a boxed warning stating denosumab increases severe hypocalcemia risk for adults with advanced CKD ...

Please provide your email address to receive an email when new articles are posted on . The FDA is investigating the risk of severe hypocalcemia in patients on dialysis treated with the osteoporosis ...

The use of the osteoporosis drug denosumab (Prolia) to prevent fractures associated with advanced chronic kidney disease (CKD) in patients on kidney dialysis significantly increases the risk for ...

According to a long-term safety study and a separate FDA internal study, Prolia had an increased risk of hypocalcemia in patients with advanced kidney disease on dialysis. Patients with advanced ...

Worsening CKD was progressively associated with denosumab-induced hypocalcemia warranting emergency treatment. Denosumab use carries a higher risk for emergency hypocalcemia compared with ...

Postoperative parathyroid hormone (PTH) showed 100% sensitivity in predicting post-thyroidectomy hypocalcemia, according to the results of a prospective study of 60 patients. Post-thyroidectomy ...

Encaleret corrected hypocalcemia and reduced hypercalciuria during the inpatient periods and the 24-week outpatient period. Mean blood levels of intact PTH, magnesium, and 1,25-dihydroxyvitamin D ...